Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



GEN Poll

More »
Jul 18, 2011

Clinical Trial Strategy

If a firm’s only candidate fails a Phase II trial, should it push on with development?

Yes
 
  33.8%
No
 
  43.2%
Undecided
 
  23.0%

Suggest a Poll
More Polls » View Results »

Unlike large biopharma firms, most small biotech companies usually have their fortunes riding on only a single drug. If a small firm’s product fails a Phase II trial, do you think the smart move is to keep working on its product candidate instead of entirely scrapping the project?

GEN Poll

More » Poll Results » Archive »

Genome Sequencing and Patient Autonomy

Do you think ACMG’s recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy?

Suggest a Poll